ScholarIQanswers from OpenAlex & ORCID
Lucio Crinò
ResearcherPublications, citations & collaboration network
Lucio Crinò is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lucio Crinò have?
ScholarIQindexed works
Lucio Crinò has 579 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lucio Crinò have?
ScholarIQcitation count
Lucio Crinò has 45,099 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lucio Crinò?
ScholarIQh-index
Lucio Crinò has an h-index of 85 in OpenAlex.
What is the i10-index of Lucio Crinò?
ScholarIQi10-index
Lucio Crinò has an i10-index of 286 in OpenAlex.
What is the ORCID of Lucio Crinò?
ScholarIQorcid
The ORCID for Lucio Crinò is on the source record.
What is the OpenAlex record for Lucio Crinò?
ScholarIQopenalex
The OpenAlex for Lucio Crinò is on the source record.
What are the most-cited papers on Lucio Crinò?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu‐Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crinò, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih‐Hsin Yang
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer